Mesoblast limited
(ASX:MSB) has achieved positive results in its clinical trial of an intravenous injection designed to aid sufferers of rheumatoid arthritis.
The regenerative medicine company says the therapy could become a first line treatment with a sustained benefit in reducing inflammation and destruction of joints.
Phase two of the clinical trial is expected to commence in the fourth quarter. Rheumatoid arthritis is the second clinical target for the company after type 2 diabetes.
In the first half of the 2012 financial year Mesoblast booked a net loss of $44.1 million.
